Patent ID: 9724382
Date: 2017-08-08
CPC Classifications: A61K,A61P

Claim:
1. A method for treating a subject suffering from or susceptible to asthma; refractory asthma; chronic obstructive bronchitis; parenchymal, fibrotic, or interstitial lung disease and/or inflammation; lung cancer; acute or chronic lung transplant rejection; undesired reaction after lung, stem cell, or bone marrow transplantation and the diseases resulting therefrom; the method comprising: (a) providing a composition comprising a cyclosporin in liposomally solubilised form, an aqueous carrier liquid, a first solubility enhancing substance selected from the group of phospholipids and a second solubility enhancing substance selected from the group of nonionic surfactants, wherein the phospholipid is a mixture of natural phospholipids and (b) administering a volume of less than 4 ml of the composition to the subject as an aerosol for pulmonary or nasal application, wherein the volume comprises a therapeutically effective dose of the cyclosporin.